Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most efficacy/positioning and several safety/interactions statements are consistent with the provided label excerpts, but there are several unsupported or over-specific claims (notably about prescribing needing antifungals/antibiotics/HIV meds, palpitations/heartbeat sensation as side effects, and ECG timing wording beyond what is explicitly stated). Missing or generalized phrasing also reduces precision (e.g., 'typical used in coronary artery disease' not directly stated).
Category Scores
Accurate Statements
Ranexa is the brand name for ranolazine.
Drug/label context: label excerpts reference Ranexa as ranolazine (e.g., Mechanism section: 'Ranoxlazine's antianginal effects...'; Drug interactions section: 'Ranolazine is primarily metabolized by CYP3A...').
Ranolazine is used to treat chronic angina (long-term angina).
INDICATIONS AND USAGE: 'Ranexa is indicated for the treatment of chronic angina.'
Ranolazine does not depend upon reductions in heart rate or blood pressure for its antianginal effects.
CLINICAL PHARMACOLOGY 12.1: '...effects ... do not depend upon reductions in heart rate or blood pressure.'
Ranolazine helps reduce angina symptoms and limit angina episodes/chest pain episodes (general claim).
CLINICAL STUDIES 14.1: CARISA and ERICA describe increased exercise duration/time to angina and decreased angina attack frequency/nitroglycerin use with Ranexa vs placebo.
Common adverse events can include dizziness, headache, constipation, and nausea.
ADVERSE REACTIONS 6.1: 'most frequently reported treatment-emergent adverse reactions ... dizziness (6.2%), headache (5.5%), constipation (4.5%), and nausea (4.4%).' Also led-to-discontinuation examples include dizziness, nausea, asthenia, constipation, and headache.
Ranolazine blocks IKr and prolongs the QTc interval in a dose-related manner.
WARNINGS AND PRECAUTIONS 5.1: 'Ranolazine blocks IKr and prolongs the QTc interval in a dose-related manner.'
Ranolazine is primarily metabolized by CYP3A and is a substrate of P-glycoprotein (P-gp).
DRUG INTERACTIONS 7.1: 'Ranolazine is primarily metabolized by CYP3A and is a substrate of P-glycoprotein (P-gp).'
Strong CYP3A inhibitors are contraindicated (and examples include ketoconazole, itraconazole, clarithromycin, etc.).
CONTRAINDICATIONS 4: 'Taking strong inhibitors of CYP3A'; DRUG INTERACTIONS 7.1: 'Do not use Ranexa with strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin...'
Clinically significant hepatic impairment is a contraindication.
CONTRAINDICATIONS 4: 'With clinically significant hepatic impairment'; USE IN SPECIFIC POPULATIONS 8.6 reiterates contraindication.
Ranolazine mechanism is anti-ischemic/antianginal effects not depending on HR/BP, and QT prolongation effect results from IKr inhibition.
CLINICAL PHARMACOLOGY 12.1: '...mechanism ... has not been determined.' and 'The QT prolongation effect ... is the result of inhibition of IKr.'
Ranolazine is taken by mouth.
DOSAGE AND ADMINISTRATION 2.1: 'Swallow Ranexa tablets whole...' and general dosing instruction implies oral administration.
Ranolazine extended-release tablets should be swallowed whole; do not crush, break, or chew.
DOSAGE AND ADMINISTRATION 2.1: 'Swallow Ranexa tablets whole; do not crush, break, or chew.'
Initiate at 500 mg twice daily and increase to 1000 mg twice daily as needed based on clinical symptoms.
DOSAGE AND ADMINISTRATION 2.1: 'Initiate Ranexa dosing at 500 mg twice daily and increase to 1000 mg twice daily, as needed, based on clinical symptoms.'
Dose doubling after a missed dose is not allowed (do not double the next dose).
DOSAGE AND ADMINISTRATION 2.1: 'If a dose ... missed ... do not double the next dose.'
Limit maximum recommended daily dose to 1000 mg twice daily.
DOSAGE AND ADMINISTRATION 2.1: 'The maximum recommended daily dose of Ranexa is 1000 mg twice daily.'
Unsupported Statements
Ranolazine is used when symptoms are not controlled well enough with other heart medicines.
Provided INDICATIONS excerpt states only 'treatment of chronic angina' and that it may be used with several therapies; it does not state failure of other medicines as a requirement.
Ranolazine is typically used in people with coronary artery disease.
The provided label excerpts do not explicitly state 'coronary artery disease' as the basis for use.
Ranolazine helps reduce angina symptoms without primarily lowering blood pressure.
The label says antianginal effects do not depend upon reductions in heart rate or blood pressure, but the claim wording 'without primarily lowering blood pressure' is not an explicit label phrase.
Ranolazine works in the heart by affecting electrical activity to improve how the heart muscle uses electrical signaling.
Label excerpt says the mechanism of action 'has not been determined' and does not describe improving electrical signaling in that way; only QT prolongation via IKr is described.
Some people feel symptom improvement after starting ranolazine therapy.
While clinical studies show reductions in angina attack frequency and increased time to angina, the provided label text excerpt does not support a generalized 'some people' phrasing.
Angina control is often evaluated over days to weeks as the medicine reaches steady effect and dosing is maintained.
No timing/steady-state evaluation timeframe is present in provided label excerpts.
Ranolazine can cause palpitations.
No palpitations adverse reaction is included in the provided adverse reaction excerpt.
Ranolazine can cause changes in how a person feels their heartbeat.
This is broader than label excerpts provided; no such specific symptom wording appears in the provided adverse reaction section.
Interactions with other medicines that also affect ECG timing can increase the risk when using ranolazine.
The label warns about QT prolongation and notes 'other QT-prolonging drugs' in the warnings excerpt, but it does not explicitly discuss 'ECG timing' phrasing or a generalized 'increase the risk when using' statement.
Interactions involving certain drug-metabolism pathways can increase the risk when using ranolazine.
This is generic; while CYP3A/P-gp interactions and QT-related risk are described, the label does not present this exact generalized statement.
Prescribing of ranolazine depends on a person’s full medication list.
The label emphasizes specific drug classes/conditions (CYP3A inhibitors/inducers, P-gp inhibitors, etc.), but does not state 'full medication list' as a requirement in the provided excerpts.
Ranolazine prescribing depends on medication review including antifungals.
Antifungals (e.g., ketoconazole, itraconazole) are mentioned in the excerpt as strong CYP3A inhibitors, but the claim 'depends on...including antifungals' is not an explicit label phrasing; also label provides drug examples rather than the term 'antifungals'.
Ranolazine prescribing depends on medication review including some antibiotics.
The provided excerpt includes erythromycin (an antibiotic) as a moderate CYP3A inhibitor, but does not broadly state 'some antibiotics' or that prescribing depends on reviewing antibiotics.
Ranolazine prescribing depends on medication review including HIV medicines.
The provided excerpt includes ritonavir/nelfinavir/indinavir/saquinavir (antiretrovirals), but does not explicitly mention HIV medicines or that review specifically depends on 'HIV medicines'.
People who are not good candidates for ranolazine may need dose adjustments.
The label excerpt specifies dose limits/adjustments in certain drug-combination contexts (e.g., with moderate CYP3A inhibitors; down-titrate with P-gp inhibitors) but does not support a broad 'not good candidates' dose-adjustment statement.
People who are not good candidates for ranolazine may need closer monitoring.
The provided label excerpts do not state 'closer monitoring' for people not good candidates.
Clinicians use ECG and medication review to manage ranolazine-related risk.
The label excerpt provided includes QT prolongation and drug-interaction risk, but does not state that clinicians use ECG and medication review specifically.
Ranolazine is usually taken in divided dosing schedules.
The label indicates twice daily dosing (divided), but 'usually taken in divided dosing schedules' is not explicit.
Ranolazine is commonly taken twice daily.
Label excerpt gives dosing '500 mg twice daily' and titration '1000 mg twice daily' but does not use 'commonly' terminology.
The ranolazine dose is adjusted based on tolerability and safety.
The label excerpt says increase 'as needed, based on clinical symptoms' and dose adjustments may be needed in combination with certain other drugs; it does not attribute adjustments to 'tolerability and safety' wording.
Contradictions
Low
AI Statement
People with significant liver impairment may not be good candidates for ranolazine.
Label Reference
CONTRAINDICATIONS 4: 'With clinically significant hepatic impairment' is contraindicated (not merely 'may not be good candidates').
Low
AI Statement
People with certain heart rhythm conditions may not be good candidates for ranolazine.
Label Reference
WARNINGS 5.1: mentions 'little experience ... exposure, other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval' but does not provide a contraindication list for 'certain heart rhythm conditions'.
Important Omissions
Do not use Ranexa with strong CYP3A inhibitors (specific examples) and avoid CYP3A inducers (specific examples) are not explicitly enumerated in the AI claims beyond generic 'ECG timing' and 'metabolism pathways'.
Importance:
Moderate
Specific contraindication about CYP3A inducers (section 4) is not explicitly stated as a contraindication in the provided AI claims.
Importance:
Moderate
Administration instruction that tablets are film-coated extended-release (and should not be crushed) is partially covered (do not crush), but tablet form/strength details are not mentioned.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Multiple safety-relevant claims are broadly consistent with QT prolongation and CYP3A/P-gp interaction concepts, but several statements are unsupported or overly generalized (e.g., palpitations/heartbeat sensation; generalized medication-list dependency; 'ECG and medication review' as a practice; 'tolerability and safety' basis for dose adjustment). These gaps could lead to incomplete or imprecise prescribing focus compared with the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided label excerpts and some safety statements are over-generalized (notably side effects such as palpitations/heartbeat sensation and prescribing dependence on specific medication categories).
Suggested Improvement
Rephrase unsupported/over-general statements to match label language: emphasize contraindications (strong CYP3A inhibitors; CYP3A inducers; clinically significant hepatic impairment), specify interaction management using label-described CYP3A/P-gp guidance (dose limits with moderate CYP3A inhibitors such as diltiazem/verapamil; down-titration with P-gp inhibitors), and limit adverse reaction claims to those explicitly listed (dizziness, headache, constipation, nausea; and discontinuation adverse events).